Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 10OTHER 6NIH 2NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Head & Neck 1Dermatologic 1

Conditions

Melanoma 1Glioma 1Brain Neoplasms 1

Interventions

Radiotherapy 58Temozolomide 37Vincristine 33Cyclophosphamide 31Etoposide 25Carboplatin 25Filgrastim 23Cisplatin 22Granulocyte Colony-Stimulating Factor 18Lomustine 14Doxorubicin 13Chemotherapy, Adjuvant 13Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Topotecan 11Radiation 11Isotretinoin 11Platinum 10sargramostim 9Specimen Handling 9Radiotherapy, Conformal 9Irinotecan 9Carmustine 91,2-diaminocyclohexaneplatinum II citrate 9etoposide phosphate 8Thiotepa 8Radiotherapy, Intensity-Modulated 8Radiosurgery 8Melphalan 8Immunohistochemistry 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × dabrafenib × CNS × Clear all
NCT04201457 2026-02-03

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Pediatric Brain Tumor Consortium

Phase 1/2 Active not recruiting
57 enrolled
CNS

Glioma

NCT02974803 2021-08-20

Concurrent Dabrafenib + Trametinib With Sterotactic Radiation in BRAF Mutation-Positive Malignant Melanoma and Brain Metastases

Canadian Cancer Trials Group

Phase 2 Terminated
6 enrolled 3 charts
CNSDermatologic

Brain Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡